Sudemycin K

Sudemycin K is a selective splicing inhibitor targeting SF3B1. Sudemycin K blocks U2 snRNP recognition of branch point sequences in pre-mRNA, inducing tumor-specific splicing deregulation and apoptosis. Sudemycin K is promising for research of SF3B1-mutated malignancies such as chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS) [1].

Product Specifications

CAS Number

[2071636-70-7]

UNSPSC

12352005

Target

SF3B1

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

C[C@H](NC(C(C)C)=O)/C=C\C(NC1CCC(C/C=C(C)/C=C/[C@@H](OC(C)(C)C2)C[C@@]32CO3)CC1)=O

Molecular Formula

C29H46N2O4

Molecular Weight

486.69

References & Citations

[1]Makowski K, et al. Sudemycin K: A Synthetic Antitumor Splicing Inhibitor Variant with Improved Activity and Versatile Chemistry. ACS Chem Biol. 2017 Jan 20;12 (1) :163-173.